We at AOP Orphan are European pioneers in the field of rare diseases, researching, developing, producing, and distributing innovative solutions worldwide since 1996. Learn more about the company here.
We at AOP Orphan focus on rare diseases particularly in the areas of HematoOncology, Cardiology & Pulmonology, Neurology & Metabolic Disorders. Learn more about the indications, its symptoms, diagnosis, therapies and everyday life here.
Our strategic goal at AOP Orphan is to constantly deliver new treatment options for the patients with rare disease. Learn more about the current product portfolio and countries' availability here.
Agile, ambitious and aligned team members, mutual appreciation and commitment - this is what makes AOP Orphan a successful company and great place to work. Learn more about the company, open positions and everyday life at AOP Orphan here.
Anagrelide AOP is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients.